Sana Biotechnology (NASDAQ:SANA) Trading Down 5.3% Following Analyst Downgrade

Sana Biotechnology, Inc. (NASDAQ:SANA)’s stock price fell 5.3% during mid-day trading on Friday after Bank of America lowered their price target on the stock from $7.00 to $6.00. Bank of America currently has a buy rating on the stock. Sana Biotechnology traded as low as $3.48 and last traded at $3.4750. Approximately 978,713 shares changed hands during mid-day trading, a decline of 69% from the average session volume of 3,114,402 shares. The stock had previously closed at $3.67.

A number of other research analysts have also recently issued reports on SANA. Wall Street Zen cut shares of Sana Biotechnology from a “hold” rating to a “sell” rating in a research note on Monday, July 20th. Rodman & Renshaw began coverage on shares of Sana Biotechnology in a research report on Monday, May 11th. They set a “buy” rating and a $16.00 target price on the stock. Finally, Weiss Ratings raised Sana Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 23rd. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $9.33.

Key Headlines Impacting Sana Biotechnology

Here are the key news stories impacting Sana Biotechnology this week:

• Positive Sentiment: Bank of America lowered its price target to $6 from $7 but maintained a Buy rating. The revised target still implies substantial upside from recent trading levels, signaling confidence in Sana’s longer-term biotechnology potential. Benzinga article
• Positive Sentiment: A separate report described analysts as bullish on Sana Biotechnology and other healthcare stocks, adding to the favorable analyst backdrop. Analysts Are Bullish on Top Healthcare Stocks
• Neutral Sentiment: HC Wainwright’s revised FY2026 loss estimate improved to $0.54 per share from $0.56, but it remains below the broader consensus estimate of a $0.59 loss. The firm expects losses of $0.14 per share in both the third and fourth quarters of 2026.
• Negative Sentiment: HC Wainwright reduced its Q3 and Q4 2026 EPS forecasts to losses of $0.14 per share from $0.13, indicating somewhat higher expected near-term cash burn.
• Negative Sentiment: The firm also cut its FY2028, FY2029 and FY2030 EPS forecasts to losses of $0.62, $0.62 and $0.45 per share, respectively. These revisions suggest profitability may take longer to achieve and are likely the main reason for the stock’s weaker tone.

Hedge Funds Weigh In On Sana Biotechnology

Large investors have recently modified their holdings of the business. BlackRock Inc. acquired a new position in Sana Biotechnology during the second quarter valued at approximately $58,196,000. Canada Pension Plan Investment Board bought a new position in Sana Biotechnology during the second quarter worth $35,662,000. Vanguard Group Inc. boosted its holdings in shares of Sana Biotechnology by 19.9% during the 3rd quarter. Vanguard Group Inc. now owns 9,128,973 shares of the company’s stock worth $32,408,000 after buying an additional 1,517,474 shares during the period. State Street Corp boosted its holdings in shares of Sana Biotechnology by 20.6% during the fourth quarter. State Street Corp now owns 8,054,841 shares of the company’s stock worth $32,783,000 after acquiring an additional 1,374,300 shares during the period. Finally, Geode Capital Management LLC boosted its stake in Sana Biotechnology by 20.3% in the 4th quarter. Geode Capital Management LLC now owns 4,118,138 shares of the company’s stock valued at $16,763,000 after purchasing an additional 694,606 shares during the period. 88.23% of the stock is currently owned by institutional investors and hedge funds.

Sana Biotechnology Stock Down 3.3%

The company’s 50 day moving average is $3.37 and its 200 day moving average is $3.45. The firm has a market capitalization of $1.06 billion, a price-to-earnings ratio of -4.67 and a beta of 2.16.

Sana Biotechnology (NASDAQ:SANA) last announced its earnings results on Tuesday, August 11th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.02. On average, analysts expect that Sana Biotechnology, Inc. will post -0.58 EPS for the current year.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.